This is a preview of subscription content,to check access.
Access this article
Armaly MF (1963) Effects of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 70:490–499
Dot C, El Chehab H, Russo A et al (2015) Ocular hypertension after intravitreal steroid injections: clinical update as of 2015. J Fr Ophtalmol 38:656–664
Malclès A, Dot C, Vie AL et al. (2016) Safety of intravitreal dexamethasone implants (Ozurdex®): the SAFODEX study. Incidence and Risk factors of Ocular Hypertension. Retina,doi: 10.1097/IAE.0000000000001369
Boyer DS, Yoon YH, Belfort R Jr et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914
Vie AL, Kodjikian L, Malcles A et al (2016) Tolerance of intravitreal Dexamethasone implants in patients with ocular hypertension or open-angle glaucoma. Retina 37(1):173–178
No funding was received for this research.
Conflict of interest
Amina Rezkallah, Ariane Malclès, declared no conflicts of interest.
Laurent Kodjikian is a consultant for Alcon, Allergan, Alimera, Bayer, Novartis and Théa.
Corinne Dot is a consultant for Bayer, Alcon, Allergan, and Novartis.
Informed consent was obtained from all individual participants included in the study.
About this article
Cite this article
Rezkallah, A., Kodjikian, L., Malclès, A. et al. DEX implant intravitreal injection, sustained intraocular hypertension, and steroid-induced glaucoma in patients with no risk factors. Graefes Arch Clin Exp Ophthalmol 256, 219–220 (2018). https://doi.org/10.1007/s00417-017-3773-z